Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Vascular lesions in the newborn

Josie A Pielop, MD
Section Editors
Moise L Levy, MD
Leonard E Weisman, MD
Deputy Editor
Rosamaria Corona, MD, DSc


Vascular lesions, including vascular neoplasms and vascular malformations, are common in newborns [1]. Although the majority of these lesions are benign and self-limited conditions, some may be part of complex syndromes or systemic disorders or may be associated with complications.

Vascular lesions presenting in the newborn will be reviewed here. Other neonatal skin lesions and inherited skin disorders are discussed separately. (See "Vesiculobullous and pustular lesions in the newborn" and "Skin nodules in newborns and infants" and "Benign skin and scalp lesions in the newborn and infant" and "Congenital melanocytic nevi" and "The genodermatoses".)


The 2014 classification of the International Society for the Study of Vascular Anomalies divides the vascular anomalies into the following broad categories [2]:

Vascular tumors, including benign, borderline, and malignant tumors

Simple malformations, including capillary malformations, lymphatic malformations, venous malformations, and arteriovenous fistula

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Sep 2017. | This topic last updated: May 10, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Kanada KN, Merin MR, Munden A, Friedlander SF. A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature. J Pediatr 2012; 161:240.
  2. Wassef M, Blei F, Adams D, et al. Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies. Pediatrics 2015; 136:e203.
  3. Mallet S, Rebelle C, Ligi I, et al. Congenital and disseminated pyogenic granuloma-like vascular lesions. Acta Derm Venereol 2015; 95:860.
  4. Browning JC, Eldin KW, Kozakewich HP, et al. Congenital disseminated pyogenic granuloma. Pediatr Dermatol 2009; 26:323.
  5. Juern AM, Glick ZR, Drolet BA, Frieden IJ. Nevus simplex: a reconsideration of nomenclature, sites of involvement, and disease associations. J Am Acad Dermatol 2010; 63:805.
  6. Cohen BA. Hemangiomas in infancy and childhood. Pediatr Ann 1987; 16:17.
  7. Metzker A, Shamir R. Butterfly-shaped mark: a variant form of nevus flammeus simplex. Pediatrics 1990; 85:1069.
  8. Oakes WJ. Butterfly-shaped mark. Pediatrics 1991; 87:956.
  9. Patrizi A, Neri I, Orlandi C, Marini R. Sacral medial telangiectatic vascular nevus: a study of 43 children. Dermatology 1996; 192:301.
  10. Ben-Amitai D, Davidson S, Schwartz M, et al. Sacral nevus flammeus simplex: the role of imaging. Pediatr Dermatol 2000; 17:469.
  11. Dompmartin A, Vikkula M, Boon LM. Venous malformation: update on aetiopathogenesis, diagnosis and management. Phlebology 2010; 25:224.
  12. Vikkula M, Boon LM, Carraway KL 3rd, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996; 87:1181.
  13. Cavalli R, Milani GP, Chelleri C, et al. Plaque-type glomuvenous malformations in a child. Lancet 2015; 386:e61.
  14. Brouillard P, Boon LM, Mulliken JB, et al. Mutations in a novel factor, glomulin, are responsible for glomuvenous malformations ("glomangiomas"). Am J Hum Genet 2002; 70:866.
  15. Hook KP. Cutaneous vascular anomalies in the neonatal period. Semin Perinatol 2013; 37:40.
  16. Tian XL, Kadaba R, You SA, et al. Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome. Nature 2004; 427:640.
  17. Dohil MA, Baugh WP, Eichenfield LF. Vascular and pigmented birthmarks. Pediatr Clin North Am 2000; 47:783.
  18. Enjolras O, Mulliken JB. The current management of vascular birthmarks. Pediatr Dermatol 1993; 10:311.
  19. Redondo P, Aguado L, Martínez-Cuesta A. Diagnosis and management of extensive vascular malformations of the lower limb: part II. Systemic repercussions [corrected], diagnosis, and treatment. J Am Acad Dermatol 2011; 65:909.
  20. Amitai DB, Fichman S, Merlob P, et al. Cutis marmorata telangiectatica congenita: clinical findings in 85 patients. Pediatr Dermatol 2000; 17:100.
  21. Memarzadeh A, Pengas I, Syed S, Eastwood DM. Limb length discrepancy in cutis marmorata telangiectatica congenita: an audit of assessment and management in a multidisciplinary setting. Br J Dermatol 2014; 170:681.
  22. Kienast AK, Hoeger PH. Cutis marmorata telangiectatica congenita: a prospective study of 27 cases and review of the literature with proposal of diagnostic criteria. Clin Exp Dermatol 2009; 34:319.
  23. Picascia DD, Esterly NB. Cutis marmorata telangiectatica congenita: report of 22 cases. J Am Acad Dermatol 1989; 20:1098.
  24. Pehr K, Moroz B. Cutis marmorata telangiectatica congenita: long-term follow-up, review of the literature, and report of a case in conjunction with congenital hypothyroidism. Pediatr Dermatol 1993; 10:6.
  25. Devillers AC, de Waard-van der Spek FB, Oranje AP. Cutis marmorata telangiectatica congenita: clinical features in 35 cases. Arch Dermatol 1999; 135:34.
  26. Eerola I, Boon LM, Mulliken JB, et al. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 2003; 73:1240.
  27. Martín-Santiago A, Knöpfel N, del Pozo J, et al. Hypotrichosis associated with capillary malformation-arteriovenous malformation syndrome. Br J Dermatol 2015; 172:450.
  28. Martínez-Glez V, Romanelli V, Mori MA, et al. Macrocephaly-capillary malformation: Analysis of 13 patients and review of the diagnostic criteria. Am J Med Genet A 2010; 152A:3101.
  29. Wright DR, Frieden IJ, Orlow SJ, et al. The misnomer "macrocephaly-cutis marmorata telangiectatica congenita syndrome": report of 12 new cases and support for revising the name to macrocephaly-capillary malformations. Arch Dermatol 2009; 145:287.
  30. Toriello HV, Mulliken JB. Accurately renaming macrocephaly-cutis marmorata telangiectatica congenita (M-CMTC) as macrocephaly-capillary malformation (M-CM). Am J Med Genet A 2007; 143A:3009.
  31. Katugampola R, Moss C, Mills C. Macrocephaly-cutis marmorata telangiectatica congenita: A case report and review of salient features. J Am Acad Dermatol 2008; 58:697.
  32. Garavelli L, Leask K, Zanacca C, et al. MRI and neurological findings in macrocephaly-cutis marmorata telangiectatica congenita syndrome: report of ten cases and review of the literature. Genet Couns 2005; 16:117.
  33. Requena L, Sangueza OP. Cutaneous vascular anomalies. Part I. Hamartomas, malformations, and dilation of preexisting vessels. J Am Acad Dermatol 1997; 37:523.
  34. Vidaurri-de la Cruz H, Tamayo-Sánchez L, Durán-McKinster C, et al. Phakomatosis pigmentovascularis II A and II B: clinical findings in 24 patients. J Dermatol 2003; 30:381.
  35. Fernández-Guarino M, Boixeda P, de Las Heras E, et al. Phakomatosis pigmentovascularis: Clinical findings in 15 patients and review of the literature. J Am Acad Dermatol 2008; 58:88.
  36. Happle R. Phacomatosis pigmentovascularis revisited and reclassified. Arch Dermatol 2005; 141:385.
  37. Huang C, Lee P. Phakomatosis pigmentovascularis IIb with renal anomaly. Clin Exp Dermatol 2000; 25:51.
  38. Van Gysel D, Oranje AP, Stroink H, Simonsz HJ. Phakomatosis pigmentovascularis. Pediatr Dermatol 1996; 13:33.
  39. Turner JT, Cohen MM Jr, Biesecker LG. Reassessment of the Proteus syndrome literature: application of diagnostic criteria to published cases. Am J Med Genet A 2004; 130A:111.
  40. Kurek KC, Luks VL, Ayturk UM, et al. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet 2012; 90:1108.
  41. Alomari AI. Characterization of a distinct syndrome that associates complex truncal overgrowth, vascular, and acral anomalies: a descriptive study of 18 cases of CLOVES syndrome. Clin Dysmorphol 2009; 18:1.
  42. Keppler-Noreuil KM, Rios JJ, Parker VE, et al. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A 2015; 167A:287.
  43. Vahidnezhad H, Youssefian L, Uitto J. Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS). Exp Dermatol 2016; 25:17.
  44. Pansuriya TC, Kroon HM, Bovée JV. Enchondromatosis: insights on the different subtypes. Int J Clin Exp Pathol 2010; 3:557.
  45. Amary MF, Damato S, Halai D, et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 2011; 43:1262.
  46. Sachs C, Lipsker D. Nevus Anemicus and Bier Spots in Tuberous Sclerosis Complex. JAMA Dermatol 2016; 152:217.
  47. Hernández-Martín A, García-Martínez FJ, Duat A, et al. Nevus anemicus: a distinctive cutaneous finding in neurofibromatosis type 1. Pediatr Dermatol 2015; 32:342.
  48. Marque M, Roubertie A, Jaussent A, et al. Nevus anemicus in neurofibromatosis type 1: a potential new diagnostic criterion. J Am Acad Dermatol 2013; 69:768.
  49. Vaassen P, Rosenbaum T. Nevus Anemicus As an Additional Diagnostic Marker of Neurofibromatosis Type 1 in Childhood. Neuropediatrics 2016; 47:190.
  50. Liu Y, Jesus AA, Marrero B, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med 2014; 371:507.
  51. Munoz J, Rodière M, Jeremiah N, et al. Stimulator of Interferon Genes-Associated Vasculopathy With Onset in Infancy: A Mimic of Childhood Granulomatosis With Polyangiitis. JAMA Dermatol 2015; 151:872.
Topic Outline